The new top 10 most expensive drugs on the planet
BioMarin’s decision last night to set the wholesale acquisition cost of its new ultra rare disease drug Brineura for CLN2 at $702,000 — with a significantly lower net amount — creates a new entry in the list of the 10 most expensive therapies in the world. With uniQure’s gene therapy Glybera unused and heading for the shelves, we also decided to drop that, leaving Horizon in the top slot with its WAC price for Horizon’s Ravicti, at *$793,632, according to the original lineup from Reinsurance Group of America. Brineura is the new number 2. We’ll also note that you could argue for a place on this list for Biogen’s Spinraza, which starts with a $750,000 price for its first year, but then drops by half, falling below the new top 10.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
